the blockade of chloride channels at several sites in the airways including mast cells, epiBackground -Inhaled frusemide inhibits airway narrowing and causes a transient thelial cells, and nerves. [2][3][4] The inhibitory effect of frusemide on hypertonic saline challenge increase in forced expiratory volume in one second (FEV 1 ) during hypertonic sa-could also be attributed in part to its potential to release prostaglandin E 2 (PGE 2 ) 5 6 which line challenge. This inhibitory effect could be secondary to prostaglandin release dur-may indirectly relax airway smooth muscle.
anti-inflammatory drugs (NSAIDs) or if they One syringe with either the frusemide or vehicle was then returned to the investigator to adhad a history of gastric ulcers. Anthropometric details, the FEV 1 measured as a percentage of minister to the subject. This was a double blind, vehicle controlled, randomised, crossthe predicted value on the control day, the dose of saline required to provoke a fall in FEV 1 of over study. 20% (PD 20 FEV 1 , ml) on the control day, and regular asthma medications are given in table 1.
       Beta 2 adrenoceptor agonists were withheld for at least six hours before the 4.5% NaCl The Fisoneb ultrasonic nebuliser (Fisons Corporation, Rochester, New York, USA) prochallenge. Six of the 14 subjects were taking inhaled corticosteroids on a daily basis for at ducing a dense aerosol with a mass median aerodynamic diameter of 4.7 m was used to least three months before the commencement of the study and the dose remained unchanged deliver both the frusemide and the vehicle.
In order to give a dose of frusemide similar for the duration of the study. All subjects were atopic, having positive skin reactions to one or to that used in a previous study, 2 6 ml of frusemide or vehicle was placed in the Fisoneb. more of eight common allergens. Subjects were asked about recent symptoms of wheeze or Subjects inhaled the aerosols for 7-9 minutes via a mouthpiece while wearing nose clips. The dyspnoea. If an increase in these symptoms occurred in the previous 24 hours then testing unit was weighed (Sartorius Analytic, Gottingen, Germany) before and after nebulisation did not proceed. No subject had a chest infection during the four weeks prior to the con-and a stopper placed in the output hole during weighing to reduce loss of volume by evaptrol visit.
The protocol was fully explained and written oration. The difference in weight change was recorded as the amount of frusemide or vehicle informed consent was obtained from each subject. The study was approved by the Central nebulised. The mean (SD) amount of frusemide nebulised for the challenge was 38.0 Sydney Health Area ethics committee.
(6.4) mg (n=26). On two occasions subjects salivated profusely back into the Fisoneb during nebulisation so these values were not included     Ampoules of frusemide (Lasix; Hoechst AG, in the calculation of the mean dose of frusemide delivered. Germany), each containing 20 mg frusemide in 2 ml (10 mg/ml), with a pH of 9, were used in the study. The vehicle was 0.9% NaCl adjusted daily by the investigator to a pH of 8.9-9.2 by     Subjects ingested 50 mg of indomethacin (Arthadding sodium hydroxide dissolved in 0.9% NaCl. A pH meter (Radiometer PHM 62, rexin, Alphapharm, Australia) twice a day (100 mg/day) or a placebo (glucose powder in Copenhagen, Denmark) was used to measure the pH of the frusemide and its vehicle. The an identical capsule) for three days before each challenge visit. osmolality of the frusemide and its vehicle was 303 mosmol as measured by freezing point deSubjects were given 12 capsules of either 25 mg indomethacin or placebo at the end of pression (Advanced Cryomatic Osmometer, Model Advanced Instruments, Massachusetts, the control day and visits 1, 2, and 3 and instructed to take two capsules twice a day in USA). Once the osmolality of the vehicle solution was adjusted, both the frusemide and the morning and at night for three days before visits 1, 2, 3, and 4. The last two capsules were the vehicle were drawn up in separate 10 ml syringes and given to a pharmacist for as-to be taken approximately 1.5 hours before coming to the laboratory. signment according to a randomisation code.
   
in FEV 1 from the baseline value the challenge was stopped and the subject included in the All subjects were assessed for airway sensitivity to oral indomethacin 15 on the control visit. study. If a 20% fall was not recorded the challenge continued for further intervals of 0.75, After recording at least a 20% fall in FEV 1 to 4.5% NaCl challenge on the control day sub-1.0, 1.5, 2.0, 4.0, 8.0, 8.0, and 8.0 minutes, or part thereof, or until a fall in FEV 1 of at jects recovered spontaneously over a one hour period after challenge. They were given either a least 20% was recorded. peak flow meter (Clement Clarke International Ltd, Harlow, Essex, UK) or an airflow meter 16 and instructed how to measure and record   their expiratory flow rates. The flow rate was Subjects were required to attend the laboratory measured before ingesting two 25 mg capsules on five occasions with a minimum of four days (50 mg) of indomethacin and every hour for separating all visits because indomethacin has six hours after ingesting the capsules. The first a half life of 2-11 hours. 18 Drug administration and second hourly measurements were taken in was randomised so that each subject received the laboratory with subsequent measurements either indomethacin and frusemide/vehicle or being carried out at home. Subjects were ex-placebo and frusemide/vehicle. cluded from the study if there was a greater than 21% variability from the expiratory flow rate measured before indomethacin.
  Eligibility for the study was assessed on the control day. On arrival at the laboratory spiro-    2 ( 2 ) metric tests (Minato Autospirometer AS500,   Osaka, Japan) were performed in triplicate and The extent to which indomethacin inhibited then repeated 10 minutes later. If there was a cyclo-oxygenase activity was determined in-less than 10% variation in the FEV 1 over 10 directly by measuring plasma levels of thromb-minutes the airways were considered stable and oxane B 2 (TXB 2 ) by radioimmunoassay (RIA). the 4.5% NaCl challenge was performed. When TXB 2 was measured because it is a stable a 20% fall from baseline FEV 1 was recorded metabolite of arachadonic acid and is found in the challenge was stopped and the PD 20 FEV 1 large quantities in plasma.
(ml) calculated. Lung function spontaneously recovered over the following 60 minutes and then airway sensitivity to 50 mg of oral indo-     methacin was assessed by measuring expiratory   flow rates over the following six hours. On visits 1, 2, 3, and 4 a 10 ml venous blood sample was taken from the forearm of each subject 17 in the 10 minute period after the 4.5%  1, 2, 3,  4 NaCl challenge. The blood was immediately On arrival at the laboratory spirometric tests transferred into a 10 ml prechilled siliconised were performed in triplicate and repeated 10 glass test tube coated with a solution of 4.5 mM minutes later. If there was less than 10% vari-EDTA and 5 g/ml of indomethacin dissolved ation in these measurements subjects inhaled in ethanol. The tube was capped and gently the frusemide or its vehicle via a Fisoneb ultrainverted several times to ensure adequate mixsonic nebuliser. Ten minutes later the spiroing of the blood sample, EDTA, and indometric tests were repeated in triplicate and the methacin. This sample was immediately placed highest recorded FEV 1 used as the baseline in ice chips and within 10 minutes was cent-FEV 1 for the 4.5% NaCl challenge. The 4.5% rifuged for 10 minutes at 2500 rpm at 4°C.
NaCl challenge was stopped when either a fall The plasma from the sample was then pipetted of more than 20% in FEV 1 was recorded or the into two 2.5 ml cryogenic tubes and "snap last dose of 4.5% NaCl aerosol was nebulised. A frozen" in liquid nitrogen for approximately venous blood sample was taken for the one minute. The frozen sample was removed measurement of TXB 2 plasma levels in the first from the liquid nitrogen and stored in a deep 10 minutes after the 4.5% NaCl challenge. freeze at −80°C. At a later date the plasma Before leaving the laboratory subjects were samples were thawed and plasma levels of given either the indomethacin or placebo cap-TXB 2 were measured using RIA (NEN Inc, sules for the next visit. They were instructed Biomedical Products Department, Boston, to take their indomethacin 1.5 hours before Massachusetts, USA).
coming to the laboratory as peak plasma concentrations are reached approximately two hours after taking indomethacin. 18   4.5%   The protocol used to perform the 4.5% NaCl challenge was similar to that described by Rodwell and colleagues, 2 although the initial    Effect of inhaled frusemide and its vehicle on inhalation periods were of a shorter duration in order to optimise the detection of changes baseline FEV 1 prechallenge
The effect of inhaling frusemide or its vehicle in FEV 1 during the initial stage of the challenge. Subjects inhaled the challenge aerosol for 0.5 on baseline lung function was assessed by calculating the difference in FEV 1 before and 10 minutes, waited one minute, then spirometric tests were performed. If there was a 20% fall minutes after inhaling these aerosols. This was group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from calculated on the days the placebo for indo-is summarised as the geometric mean with 95% confidence intervals. A Student's paired t test methacin was given.
was used to test differences between paired mean data and a Pearson's or Spearman's correlation test for relationships between variables. PD 20 FEV 1 to 4.5% NaCl challenge The provocative dose of 4.5% NaCl (ml) caus-Differences were considered significant at p<0.05. ing a 20% fall from the baseline FEV 1 (PD 20 FEV 1 ) was calculated and reported as the geometric mean with 95% confidence intervals. Changes in PD 20 FEV 1 between study days Results  1  :     1-4 were reported as the fold change with 95% confidence intervals.
On arrival at the laboratory there was less than a 20% difference in the FEV 1 between the control day and subsequent visits.
Percentage rise in FEV 1 during challenge
The transient bronchodilation or the percentage rise in FEV 1 from the baseline pre-          1 :  challenge FEV 1 during challenge (% rise) was calculated by subtracting the highest FEV 1 (l) There was a small increase of 0.06 l (0 to 0.12) from baseline FEV 1 10 minutes after inhaling recorded during challenge from the prechallenge FEV 1 (l) and expressing this differ-frusemide and a decrease of 0.07 l (−0.13 to −0.01) after inhaling the vehicle (p=0.03, ence as a percentage of the prechallenge FEV 1 (l). n=14). These changes were considered not clinically significant.
Maximum percentage rise in FEV 1 during challenge    20  1    4.5%  The maximum percentage rise recorded on the two days frusemide was inhaled was calculated. On the days frusemide was inhaled there was a significant increase in the PD 20 FEV 1 to 4.5% At the greater of the these two values the cumulative dose of 4.5% NaCl (ml) was re-NaCl challenge. In the presence of indomethacin the mean PD 20 FEV 1 increased from corded, thus giving an indication when the maximum percentage rise in FEV 1 occurs dur-5.4 ml (2.9 to 9.9) after inhaling the vehicle to 20.2 ml (14.5 to 28.4) after inhaling frusemide ing challenge. The significance of the maximum percentage rise in FEV 1 during challenge with (p<0.001, n=14), which represented a 3.7 (2.0 to 7.3) fold increase. In the presence of placebo 4.5% NaCl was then tested by comparing the percentage rise on the frusemide day with the the PD 20 FEV 1 increased from 4.9 ml (2.5 to 9.6) after inhaling the vehicle to 16.3 ml (11.2 percentage rise on the vehicle day at the same delivered dose of 4.5% NaCl. For example, if to 23.7) after inhaling frusemide (p<0.001, n= 14), a 3.3 (2.0 to 5.4) fold increase. the maximum percentage rise in FEV 1 occurred after 5 ml on the placebo/frusemide day, then
The fold increase in PD 20 FEV 1 caused by frusemide was similar in the presence of indoit was compared with the corresponding percentage rise in FEV 1 at 5 ml on the placebo/ methacin and placebo (3.7 (2.0 to 7.3) versus 3.3 (2.0 to 5.4); p=0.61, n=14). Indovehicle day. The comparison of the maximum percentage rise between inhaled frusemide and methacin therefore had no effect on the increase in PD 20 FEV 1 caused by frusemide. vehicle was therefore performed only in the presence of indomethacin or placebo.
When the vehicle was inhaled there was no significant difference in the PD 20 FEV 1 between the indomethacin and placebo days with the mean fold difference being 0.9 (0.6 to 1.4); Differences in plasma TXB 2 levels Plasma levels of TXB 2 (pg/ml plasma) were p=0.66 (n=14).
There was a range of asthma severity 19 within compared between the indomethacin and the placebo study days.
the group (table 1) with the mean PD 20 FEV 1 being 4.2 ml (2.5 to 7.1) which is considered to be in the moderate range. Three subjects had severe asthma (PD 20 FEV 1 Ζ2 ml), six Relationship between TXB 2 levels and percentage rise in FEV 1 had moderate asthma (PD 20 FEV 1 >2 ml and Ζ6 ml), and five had mild asthma (PD 20 FEV 1 The mean difference in plasma TXB 2 levels on the placebo/vehicle and indomethacin/fru->6 ml). Two subjects (11 and 13) contracted a mild chest infection after visit 3 and therefore semide days and the mean difference in the percentage rise in FEV 1 on the placebo/vehicle there was a period of 28 and 29 days, respectively, between visits 3 and 4. and indomethacin/frusemide days were calculated. A Spearman's rank correlation was then performed on these calculated differences.
    1   Frusemide, when inhaled by asthmatic subjects before challenge with 4.5% NaCl, caused a   Data are presented as mean with 95% con-transient rise in FEV 1 which was not blocked by indomethacin or its placebo (3.6% (1.2 to fidence intervals or the mean and its range. The PD 20 FEV 1 (ml) to 4.5% NaCl challenge 6.0) versus 3.1% (1.0 to 5.2)) with a mean group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from difference of 0.6% (−1.7 to 2.9); p=0.
(n= Discussion
The results show that the transient bron-14). When the vehicle was inhaled there was a fall from the baseline FEV 1 during challenge chodilation caused by inhaled frusemide during the initial stages of airway challenges 2 19 20 has in the presence of indomethacin and its placebo (−4.8% (−8.2 to −1.5) versus −2.2 (−6.9 been reproduced in this study and that indomethacin had no effect on the decrease in to 2.5)) with a mean difference of −2.6% (−6.4 to 1.2); p=0.19 (n=14).
airway sensitivity to 4.5% NaCl challenge caused by frusemide. It is therefore unlikely There was an inverse relationship between the prechallenge FEV 1 recorded after subjects that prostaglandins are involved in the transient bronchodilation and the decrease in airway inhaled the frusemide and the percentage rise in FEV 1 recorded during challenge (r=−0.469, sensitivity to 4.5% NaCl challenge as indomethacin, a prostaglandin synthetase inhibitor, p<0.02, n=28). This suggests that the lower the prechallenge FEV 1 the greater is the per-is not effective in inhibiting these responses.
These findings are supported by the results of centage rise during the challenge. studies performed in human nasal mucosa 21 where frusemide did not cause an increase in PGE 2 levels. The significant bronchodilation during chal-     1  lenge observed in the presence of approximately  40 mg frusemide occurred after 2 ml of 4.5% The mean (95% CI) highest percentage rise in NaCl had been nebulised. This broncho-FEV 1 during 4.5% NaCl challenge was 4.9% dilation during challenge has not been de-(2.6 to 7.1) which occurred after (geometric scribed in previous studies where smaller doses mean with 95% CI) 1.96 ml (1.1 to 3.5) of of frusemide have been nebulised. [22] [23] [24] [25] [26] [27] With 4.5% NaCl had been nebulised. The maximum the inhalation of larger doses of frupercentage rise occurred on the placebo/frusemide (40-80 mg) bronchodilation has been semide day in nine of the 14 subjects and on observed. 2 20 28 Thus, the protective effect of the indomethacin/frusemide day in the refrusemide which we observed against airway maining five subjects. At the common nebuchallenge may be partly attributable to its bronlised dose of saline (1.96 ml (1.1 to 3.34)) there chodilating action, but only at higher doses. was a 4.9% (2.6 to 7.1) rise from baseline FEV 1 This is the first study to investigate the tranon the frusemide day compared with a fall of sient bronchodilation observed in the presence −9.6% (−13.8 to −5.4) from baseline FEV 1 of frusemide during 4.5% NaCl challenge in on the corresponding vehicle day. The mean asthmatic subjects. During exercise challenge difference between the rise from baseline FEV 1 a single maximum stimulus dehydrates the airin the presence of frusemide and the fall from ways and a dose-response curve cannot be baseline in the presence of vehicle was 14.5%
constructed. Subtle changes in lung function (9.4 to 19.6); p<0.001 (n=14).
would therefore be missed during exercise challenge. Also, if subjects were at their best lung function before the start of challenge then it is unlikely that bronchodilation would be ob-  2  served during the challenge. All subjects in the Plasma levels of TXB 2 measured in the pres-present study were either at less than 90% of ence of indomethacin were lower than the levels their predicted FEV 1 or were known to have at measured on the placebo day with the mean least a 10% increase in FEV 1 after inhaling difference being 154.8 pg/ml (62.5 to 247.1); a bronchodilator. Airways obstruction before p=0.002 (n=28). The results suggest that challenge maximises the opportunity to observe indomethacin inhibited but did not completely transient bronchodilation during challenge. In block the formation of plasma TXB 2 .
fact, there was an inverse correlation between lung function and the transient bronchodilation caused by frusemide -that is, the lower the prechallenge lung function the greater the percentage rise in FEV 1 during challenge.    2       1
Inhaled frusemide also caused a small increase in the prechallenge FEV 1 and an increase Indomethacin significantly reduced plasma TXB 2 levels compared with its placebo. The in the PD 20 FEV 1 to 4.5% NaCl aerosol, both of which were unaffected by premedication mean difference in plasma TXB 2 levels between the indomethacin and placebo days was 73 pg/ with indomethacin.
This study shows that indomethacin has no ml (17.0 to 129.4); p=0.01 (n=14). The percentage rise during challenge with 4.5% NaCl effect on the decrease in airway sensitivity to 4.5% NaCl challenge caused by frusemide. was greater in the presence of frusemide than its vehicle with the mean difference being −5.8% The 3.3-fold decrease in PD 20 FEV 1 on the placebo day was not significantly different from (−11.2 to −0.4); p=0.04 (n=14). There was, however, no significant correlation between the the 3.7-fold decrease in PD 20 FEV 1 on the indomethacin day. Plasma TXB 2 levels were reduction in plasma TXB 2 levels and the effect of frusemide on lung function during challenge significantly lower on the days of indomethacin administration, indicating that subjects had (r S =0.13; p=NS, n=14).
Individual dose-response curves for the five taken their capsules as instructed. We selected a dose of 100 mg/day indostudy days for the 14 subjects who participated in this study are shown in fig 1. methacin because it blocks refractoriness to group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from Cumulative dose of 4.5% NaCl (ml) group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from ultrasonically nebulised distilled water 29 which onset of airway narrowing by initially blocking the release of mast cell mediators 3 while bronis thought to be mediated by prostaglandins. This result suggests that the prostaglandins chodilating mediators such as VIP and NO are being released in response to the hypertonic released in the airways by non-isotonic aerosol challenge are inhibited by taking 100 mg/day stimulus. As the hypertonic stimulus continues, frusemide becomes ineffective at blocking mast of oral indomethacin for three days before challenge. If inhaled frusemide (40 mg) enhances cell mediator release and these bronchoconstricting mediators override the bronchoairway prostaglandin release, causing a rise in FEV 1 during hyperosmolar saline challenge, dilating effect of VIP and/or NO. Secondly, frusemide may block the release of neurothen 100 mg/day indomethacin should at least partially inhibit prostaglandin production and transmitters from the excitatory nonadrenergic non-cholinergic nervous system reduce the rise in FEV 1 during challenge.
Investigators have suggested that broncho-(eNANC) such as substance P which causes contraction of bronchial smooth muscle. 38 With constrictor prostaglandins are released during indirect airway challenges such as water and the temporary blockade of eNANC neurotransmitters the iNANC system would be unmetabisulphite. 30 31 When these investigators gave either oral 31 or inhaled 31 cyclo-oxygenase opposed and this would account for the observed transient bronchodilation. Whether inhibitors before challenge there was a significant improvement in airway sensitivity to frusemide preferentially blocks the eNANC nervous system is uncertain as this action of these challenges. This improvement was enhanced in the presence of frusemide. In our frusemide has not been studied. Thirdly, the release of VIP and NO in the presence of a study indomethacin did not improve airway sensitivity when taken before 4.5% NaCl chal-hypertonic stimulus may be dependent upon blocking a frusemide sensitive chloride channel, lenge or when taken in combination with inhaled frusemide. This suggests that broncho-possibly at airway sensory nerves.
2 4 Finally, a hypertonic stimulus in combination with fruconstricting prostaglandins are not released during challenge with 4.5% NaCl or that ad-semide may stimulate the release of bronchodilating mediators from airway epithelium. equate pulmonary cyclo-oxygenase inhibition was not achieved in all subjects. Our study, Studies performed in equine trachealis muscle have shown that frusemide inhibited cholinhowever, is the first to attempt to record objectively the effectiveness of cyclo-oxygenase ergic nerve stimulation; however, this response was dependent on the epithelium being intact. 39 inhibition by measuring TXB 2 levels on both indomethacin and placebo days. Unlike pre-More recently Verleden and colleagues 40 have shown, in human bronchial tissue where the vious studies, we have evidence to support the inhibition of prostaglandin production by epithelium had been removed, that frusemide in combination with indomethacin was effectindomethacin as there was a significant reduction in TXB 2 levels on the days indo-ive at inhibiting cholinergic contraction of the tissue. methacin was taken. What is uncertain is whether this dose was effective at reducing
In conclusion, this study shows that prostaglandins are unlikely to be responsible for the airway prostaglandin activity.
The fact that indomethacin had no effect on transient bronchodilation observed in the presence of frusemide during 4.5% NaCl challenge the transient bronchodilation observed in the presence of frusemide during 4.5% NaCl chal-in asthmatic subjects. lenge suggests that PGE 2 was not implicated 
